Deep Dive Episode 118 – Can Patents and Bayh-Dole Fuel Innovation in the Time of COVID-19?

Activists and politicians have responded to the worldwide COVID-19 pandemic by calling for the elimination of patent rights on treatments or cures. Some have even called for outright confiscation by the government of any patents on tests, treatments, and vaccines. This live podcast will discuss how the biopharmaceutical industry has responded to the COVID-19 pandemic and consider the role played by reliable and effective patent rights in biotech innovations in making this response possible.

Are patents and patent licensing, including the licensing of university-patented inventions through the Bayh-Dole regime, essential legal and economic drivers of successful innovation in 21st-century healthcare? How might patents, patent licensing, and the tech transfer process created by the Bayh-Dole Act provide key legal and policy tools for companies to respond effectively to our current health crisis and crises to come? These and other questions will be discussed in this live podcast.

Lesley Millar-Nicholson

Director, Technology Licensing Office & Director, Catalysts, Office of Strategic Alliances & Technology Transfer


Brian O’Shaughnessy

Partner, Dinsmore & Shohl LLP and

Past President, Licensing Executives Society, USA & Canada

Corey Salsberg

Vice President, Global Head IP Affairs


Adam Mossoff

Professor of Law

Antonin Scalia Law School, George Mason University

Intellectual Property

The Federalist Society and Regulatory Transparency Project take no position on particular legal or public policy matters. All expressions of opinion are those of the speaker(s). To join the debate, please email us at [email protected].

Related Content

Skip to content